US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere...
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of...
US biopharma AbbVie is to take over Belgian biotech Syndesi Therapeutics, in a move that will expand its neuroscience portfolio. Under the agreed terms, AbbVie will pay...
US biopharmas AbbVie and Regenxbio are forming a strategic partnership to develop and commercialize a gene therapy for eye diseases. The transaction is expected to close...
US pharma AbbVie has put compatriot Allergan’s women’s health business up for sale. The company is said to be working with Morgan Stanley on an auction process that has...
US biopharma AbbVie and compatriot biotech Caribou Biosciences have entered into a multi-year collaboration and license agreement to research and develop chimeric antigen...
US biopharma AbbVie has signed a global collaboration agreement with China’s I-Mab to develop and commercialize lemzoparlimab – also known as TJC4 – an anti-CD47...
17.06.2020
- US drugmaker AbbVie has signed two separate collaboration agreements, one with Denmark’s Genmab and the other with China’s Jacobio Pharmaceuticals, for developing and...
